CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Sino Biopharmaceutical Enters Partnership With Boehringer Ingelheim With Potential Deal Value Of $7 Bln

By Reuters News

Nov 4 (Reuters) - Sino Biopharmaceutical Limited 1177.HK:

  • SBP GROUP ENTERS PARTNERSHIP WITH BOEHRINGER INGELHEIM WITH POTENTIAL DEAL VALUE OF $7 BILLION

  • ENTER INTO PARTNERSHIP WITH BOEHRINGER INGELHEIM WITH POTENTIAL TOTAL DEAL VALUE OF US$7 BILLION

  • SBP GROUP TO RECEIVE $358 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS

  • SBP GROUP ELIGIBLE FOR $7 BILLION IN MILESTONE PAYMENTS PLUS DOUBLE-DIGIT ROYALTIES

  • AGREEMENT COVERS SIX PRECLINICAL ASSET PROGRAMS SPANNING ADCS AND T-CELL ENGAGERS

  • BOEHRINGER INGELHEIM MAY BUY EXCLUSIVE RIGHTS TO SIX PROGRAMS UNDER AGREEMENT


Further company coverage: 1177.HK

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk